- Policy
- Only 6% of domestic medical staff received the vaccines
- by Lee, In-Bok Feb 25, 2020 06:12am
- A large number of university hospital staff in Korea are treating patients without even receiving a preventive vaccine recommended for medical workers. Even 93.5% of administrators for Hospital Infection did not have all the recommended vaccines. As most of the reasons for the difficulty in vaccinating are the cost burden, the government need
- Company
- COVID-19 delays Cancer Deliberation Committee review
- by Eo, Yun-Ho Feb 25, 2020 06:12am
- The 2019 novel coronavirus, COVID-19, is even affecting pharmaceutical reimbursement listing procedure. According to pharmaceutical industry source, the Korean health authority has canceled the Cancer Treatment Deliberation Committee’s meeting initially scheduled on Feb. 26. Pharmaceutical companies that have been waiting for the de
- Company
- Prescription guidance and label change for Xeljanz on UC
- by Nho, Byung Chul Feb 25, 2020 06:11am
- The Korean health authority is predicted to narrow down the use of Pfizer’s treatment for patients with ulcerative colitis, Xeljanz (tofacitinib citrate) soon. Ministry of Food and Drug Safety (MFDS) is expected to conclude its decision on pharmaceutical safety and revising related indication of Xeljanz, as discussed in-depth with Pfizer
- Company
- Fresenius labor union conflict with management intensifies
- by An, Kyung-Jin Feb 25, 2020 06:11am
- The conflict between labor union and the management of Fresenius Medical Care (FMC) has emerged as the union intensified the fight against the management, who has been uncooperative in paying employees over 14 months and inking an agreement. Korea Democratic Pharmaceutical Union’s FMC Chapter has co-convened a press conference with UNI-G
- Company
- Pneumonia vaccine & immune booster sales surged
- by Kim, Jin-Gu Feb 25, 2020 06:11am
- COVID-19 outbreak lasted for one month, and sales of pneumococcal vaccines and immune boosters also increased. According to the industry on the 20th, Pfizer's pneumococcal vaccine, Prevenar 13, Prevena 13 sales soared during COVID-19 outbreak. According to Chong Kun Dang, which is currently in charge of domestic sales of Prevenar, Preve
- Opinion
- [Reporter’s view] Regional infection of COVID-19 has spread
- by Lee, Hye-Kyung Feb 25, 2020 06:10am
- On the 18th, the HIRA turned upside down when news of the first positive COVID-19 patient occurred in Daegu. It was reported that a family of the HIRA’s Daegu branch staff members worked in Daegu Saeronan Hospital, where patient 31 suspected of being a ‘super spreader’ of the spread of community infection in COVID-19, was working. The
- Policy
- Nocdurna SL benefits are newly established
- by Kim, Jung-Ju Feb 25, 2020 06:09am
- The new benefit standard for the pituitary hormone, Nocdurna Sublingual tab (Desmopressin acetate), which is used for the treatment of nocturnal urine, will be applied from next month. However, because The drug’s benefit would be limited to only for idiopathic nocturnal polyuria, and it is not eligible for primary urination and nocturnal
- Company
- Reimbursed Imfinzi available for stage 3 lung cancer soon
- by Eo, Yun-Ho Feb 24, 2020 06:28am
- The first immunotherapy option for patients with stage 3 lung cancer, Imfinzi, would soon receive healthcare reimbursement. According to pharmaceutical industry, AstraZeneca and National Health Insurance Service (NHIS) have reached an agreement on the pricing of PD-11 inhibitor Imfinzi injection (duvalumab). The reimbursed indication is
- Opinion
- [Column] Regulations hindering healthcare IT development
- by Jung, Hye-Jin Feb 24, 2020 06:27am
- People say ‘data is petroleum of the future.’ ‘Big Data’ is the key resource and product of data economics and digital economics, but also is a key factor deciding the state competitiveness. With the recently passed Three Data Bills, anonymous information system has been adopted and obfuscated data incorporation between companies or
- Policy
- The ruling & opposition parties agreed to COVID-19 committee
- by Lee, Jeong-Hwan Feb 24, 2020 06:27am
- The parliament barely agreed to form a special committee for the COVID-19. It will be officially launched when it is processed at the plenary session on the 24th. The official name was the National Assembly COVID-19 special committee, and the chairman was appointed by the Democratic Party. On the 20th, a member of the Democratic Party, Hud
